Related Experiment Videos
Phloroglucinol in irritable bowel syndrome
Wasim Jafri1, Javed Yakoob, Sajjad Hussain
1Department of Medicine, Aga Khan University Hospital, Karachi.
JPMA. the Journal of the Pakistan Medical Association
|February 4, 2006
Summary
Phloroglucinol effectively treats Irritable Bowel Syndrome (IBS) symptoms like pain and bloating. This antispasmodic agent is well-tolerated, offering significant relief for most IBS patients.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Irritable Bowel Syndrome (IBS) is a common gastrointestinal disorder characterized by abdominal pain and altered bowel habits.
- Antispasmodic agents are frequently used to manage IBS symptoms, but their efficacy varies.
Purpose of the Study:
- To evaluate the effectiveness and tolerability of phloroglucinol as a treatment for Irritable Bowel Syndrome (IBS).
Main Methods:
- An open-label, quasi-interventional study involving 100 IBS patients diagnosed by Rome II criteria.
- Patients received phloroglucinol 50mg orally three times daily for two months.
- Symptom assessment was conducted before and during treatment using a questionnaire.
Main Results:
- Phloroglucinol treatment led to statistically significant improvements in abdominal pain, stool frequency, urgency, mucus passage, incomplete defecation, and bloating (p<0.001).
- No significant improvement was observed in straining.
- Females showed a statistically significant improvement in the sense of incomplete defecation (p=0.003).
Conclusions:
- Phloroglucinol, at a dosage of 50mg three times daily, is an effective and well-tolerated treatment for IBS.
- The medication provides relief for the majority of IBS-related symptoms.
Related Concept Videos
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:17Irritable Bowel Syndrome I: Introduction
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...